RxDoctor Payments Data

Eric Lu, PA

Physician Assistant · Anaheim, CANPI 1841498565

Payments from drug & device makers

$4,663in general payments, 2019–2025

Across 215 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$779
  • AstraZeneca$570
  • Amgen$566
  • Lilly USA, LLC$499
  • Novo Nordisk$417
  • Pfizer$379
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,644100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,663 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$58,485
Medicare patients
161
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol217$167,797
JardianceEmpagliflozin99$85,331
TrulicityDulaglutide58$66,892
RybelsusSemaglutide60$61,719
KerendiaFinerenone47$45,648
OzempicSemaglutide40$36,581
JanuviaSitagliptin Phosphate48$36,274
EliquisApixaban32$28,883
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$27,114
MyrbetriqMirabegron31$25,183
Breo ElliptaFluticasone/Vilanterol51$22,535
ArexvyRsvpref3 Antigen/As01e/Pf63$18,067
XareltoRivaroxaban16$16,643
VascepaIcosapent Ethyl52$14,568
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$13,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$570$181,109232 claims
Novo NordiskRybelsus, Ozempic$417$98,301100 claims
Boehringer IngelheimJardiance, Tradjenta$165$97,447115 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$174$73,493178 claims
Lilly USA, LLCTrulicity$499$66,89258 claims
BayerKerendia$779$45,64847 claims
MerckJanuvia$95$36,27448 claims
PfizerEliquis$379$28,88332 claims
Johnson & JohnsonXarelto$195$16,64316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Anaheim

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →